Skip to main content
ADC Therapeutics SA logo

ADC Therapeutics SA — Investor Relations & Filings

Ticker · ADCT ISIN · CH0499880968 US Manufacturing
Open in API
Filings indexed 398 across all filing types
Latest filing 2026-06-03 Regulatory Filings
Country US United States of America
Listing US ADCT

About ADC Therapeutics SA

https://adctherapeutics.com/

ADC Therapeutics SA is a commercial-stage biotechnology company pioneering the development of antibody-drug conjugates (ADCs) for cancer therapy. The company focuses on creating highly potent and targeted ADCs to treat hematologic malignancies and solid tumors, addressing significant unmet medical needs. Its primary product, ZYNLONTA® (loncastuximab tesirine-lpyl), is an FDA-approved anti-CD19 ADC for adults with relapsed or refractory large B-cell lymphoma. The company's research and development pipeline includes a next-generation PSMA-targeting ADC that utilizes a differentiated exatecan-based payload with a novel hydrophilic linker, aimed at treating solid tumors.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 80% confidence The document is a United States SEC Form 8-K “Current Report” describing Regulation FD disclosure (press release and presentation) and other events (topline clinical trial data), with exhibits attached (press release and presentation). It is not a full annual or interim report, nor a specific management discussion, earnings release, dividend notice, share issuance, or governance change. As an 8-K current report, it falls under general regulatory announcements. Therefore, it is classified as a Regulatory Filing (RNS).
2026-06-03 English
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a current report on Form 8-K detailing Item 5.07, which provides the final results of shareholder votes on various proposals at the 2026 Annual General Meeting. It lists each proposal and the votes For, Against, Abstain, and Broker Non-Votes. This matches the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA).
2026-06-02 English
8-K - ADC Therapeutics SA (0001771910) (Filer)
Report Publication Announcement Classification · 85% confidence The document is a Form 8-K current report that is only 3,416 characters long and does not include substantive financial results itself, but rather states that a press release announcing first-quarter results “is attached” as Exhibit 99.1. Under the “menu vs meal” rule, such a short notice that announces the release of a report (the press release) qualifies as a Report Publication Announcement (RPA), not an actual earnings release document.
2026-05-04 English
DEF 14A - ADC Therapeutics SA (0001771910) (Filer)
Proxy Solicitation & Information Statement
2026-04-20 English
EFFECT - ADC Therapeutics SA (0001771910) (Filer)
Regulatory Filings
2026-03-17 English
8-K - ADC THERAPEUTICS SA (0001771910) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content includes an amendment to a Purchase and Sale Agreement and issuance of warrants, which are financing-related activities. There are no financial statements or detailed financial performance data presented, so it is not an Annual Report (10-K) or Interim Report (IR). The document is not a proxy, call transcript, or governance report. It is a regulatory filing announcing material definitive agreements and unregistered sales of equity securities, which fits the Capital/Financing Update category. The document length is 9495 characters, which is substantive and contains detailed information about the financing amendment and warrant issuance. Therefore, the best classification is Capital/Financing Update (CAP).
2026-02-23 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.